Researcher suggests enzyme crucial to embryonic development

(Medical Xpress)—Scientists have long recognized retinoic acid – a compound the body produces by metabolizing vitamin A – as crucial to embryonic development. Either too much or too little retinoic acid during gestation can lead to a number of severe postnatal complications and diseases. Consequently, much research has been done on how the body regulates the metabolism of vitamin A, though no clear consensus has emerged.

But new research by Alexander Moise, University of Kansas assistant professor of pharmacology and toxicology, suggests the key to vitamin A metabolism could be an enzyme called dehydrogenase reductase, or DHRS3. According to Moise, this finding could mean a new framework for understanding and treating disorders related to impaired vitamin A metabolism ranging from congenital defects to immune deficiency to skin disorders and blindness.

"Alterations in vitamin A metabolism during pregnancy can lead to various developmental disorders and diseases," said Moise, a faculty member in the KU School of Pharmacy. "That's why we want to better understand the mechanisms by which the body controls retinoic acid balance. We find the enzyme DHRS3 could be crucial to that process."

Moise's findings are available online and will appear this fall in The FASEB Journal, the official publication of the Federation of American Societies for Experimental Biology.

Moise's central hypothesis is that retinoic acid regulates its own levels via a homeostatic feedback mechanism – a self-correcting system that maintains equilibrium by balancing the formation of retinoic acid and its breakdown. But current studies have largely ignored the role of enzymes that carry out the reduction of the metabolite retinaldehyde in retinoic acid metabolism.

Moise and his colleagues address this gap and focus on the enzyme DHRS3. In their recent study, the researchers demonstrate that DHRS3-deficient mice saw a 40 percent increase in retinoic acid, which lead to developmental defects, including common human congenital defects such as cleft palate, skeletal defects and defects in heart development. These DHRS3-deficient mice died during gestation.

"We find that DHRS3 is pivotal in the reduction of retinaldehyde and, thus, pivotal in preventing the formation of excess retinoic acid during ," he said. "Previously, the consensus had been that formation of excess retinoic acid is prevented largely through its breakdown by cytochrome P450 enzymes. Or put another way: While the previous model has been that the body prevents formation of excess retinoic acid by slamming on the brakes, DHRS3 takes the foot off the gas when it comes to vitamin A metabolism."

The specific goal of Moise's current project is to determine the factors that control the formation of retinoic acid in vivo. But longer term, the goal is to discover targets that allow for the manipulation of the levels and activity of in target tissues and to develop improved approaches to prevent and treat congenital disorders, blinding and immune diseases and cancer.

"This could have major implications for thousands, maybe millions, of people each year," he said.

More information: www.fasebj.org/content/early/2… 227967.full.pdf+html

Related Stories

Study shows how embryos regulate vitamin A derivatives

Nov 20, 2007

Human embryos that get too much or too little retinoic acid, a derivative of Vitamin A, can develop into babies with birth defects. New research at UC Irvine shows for the first time how embryonic cells may regulate levels ...

Keeping retinoic acid in check

Apr 19, 2011

Neurobiologists from the Friedrich Miescher Institute for Biomedical Research (FMI) of the Novartis Research Foundation are the first to describe a mechanism that controls the synthesis of retinoic acid in ...

Embryology study offers clues to birth defects (w/Video)

Jun 09, 2009

Gregg Duester, Ph.D., professor of developmental biology at Burnham Institute for Medical Research (Burnham), along with Xianling Zhao, Ph.D., and colleagues, have clarified the role that retinoic acid plays in limb development. ...

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.